Allogeneic stem cell transplantation from donors with mosaic Turner syndrome
β Scribed by Manola, K N; Sambani, C; Karakasis, D; Baltathakis, I; Zoumbos, N; Symeonidis, A
- Book ID
- 110015084
- Publisher
- Nature Publishing Group
- Year
- 2006
- Tongue
- English
- Weight
- 73 KB
- Volume
- 38
- Category
- Article
- ISSN
- 0007-1188
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Autoantibody production following allogeneic stem-cell transplantation is common and is often ascribed to the immune dysregulation associated with graft-versus-host disease. Recent data suggests that donor-memory B cells can be reactivated on exposure to antigen and result in antibody production in
## Abstract Allogeneic hematopoietic stem cell transplantation (SCT) is a potentially curative treatment for patients with myelodysplastic syndrome (MDS). Relapses after transplantation however, are not uncommon and are usually due to reβemergence of a recipient derived, neoplastic, stem cell clone